Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazoprevir/Elbasvir + TACE in HCV-associated HCC
NCT03110055Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- May 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of grazoprevir and elbasvir in hepatitis C (HCV) and hepatocellular carcinoma (HCC), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoints: Overall survival at 24 months, Adverse events and serious adverse events at 24 months and 3 more. Status: unknown.
02
Drugs
grazoprevirelbasvir
03
Conditions
hepatitis C (HCV)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03110055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110055.